CBP Rulings
Index coverage and update dates
- Indexed
- 6,578 rulings
- NY rulings from
- Nov 2024
- Newest here
- Nov 12, 2026
- Newest on CBP
- Nov 13, 2026
- Customs Bulletin through
- Nov 18, 2026
- Last sync with CBP
- 1 hour ago
- NY N351520Aug 18, 2025
The tariff classification of Ferric Citrate Tablets and Bosentan Tablets for Oral Suspension in dosage form from India
In your letter dated July 21, 2025, you requested a tariff classification ruling. Ferric Citrate, imported in 210 mg tablets, is in a class of medications called phosphate binders. It is indicated for the treatment of hyperphosphatemia (elevated level of phosphate in the blood) in patients with chronic kidney disease (CKD) who are on dialysis. Ferric Citrate is also used to treat iron deficiency anemia in patients with CKD who are not on dialysis. Bosentan for oral suspension, imported in 32 mg tablets, is a dual endothelin receptor antagonist.
- NY N348833Jun 6, 2025
The tariff classification of Potassium Chloride Powder for Oral Solution in dosage form, from the United States
In your letter dated May 9, 2025, you requested a tariff classification ruling. Potassium Chloride Powder, imported in 20 mEq for Oral Solution, is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis. In your letter, you stated the country of origin will be the United States and exported from India.
- NY N347734May 8, 2025
The tariff classification of Peritoneal Dialysis (PD) solutions of Extraneal® (icodextrin) and Dianeal® (dextrose), in dosage form, from Mexico
In your letter dated April 11, 2025, filed on behalf of Vantive US Healthcare LLC, you requested a tariff classification ruling. We note that the request did not seek a determination as to country of origin, or as to the applicability of preferential treatment under the U.S.-Mexico-Canada Agreement; as such, this ruling does not address those issues. The Peritoneal Dialysis (PD) solutions imported in ultrabags are used to remove excess fluid, correct electrolyte problems, and remove toxins in those with kidney failure.
- NY N343512Nov 13, 2024
The tariff classification of Sevelamer Hydrochloride Tablets in dosage form, from India
In your letter dated October 24, 2024, you requested a tariff classification ruling. Sevelamer Hydrochloride, imported in 800 mg tablets, is a phosphate binder used to treat hyperphosphatemia, an electrolyte disorder in which there is an elevated level of phosphate in the blood. It is also used to control phosphorus levels in patients with chronic kidney disease who are on dialysis.
Source: rulings.cbp.gov (CROSS). This index holds New York rulings issued since Nov 2024 and the Headquarters rulings they cite. It is not the full CROSS database of 222,467 rulings, and it does not hold every Headquarters ruling. New rulings usually appear here within a few days of CBP publishing them; a ruling published long after its number was assigned can take several weeks. Revoked, modified and proposed marks come from the weekly Customs Bulletin, where CBP publishes most such actions under 19 U.S.C. 1625(c), read here from the Nov 2024 issues onward, and from the subjects of indexed Headquarters rulings. A revocation is marked from the date it takes effect. The absence of a mark is not confirmation that a ruling is still in effect. A ruling letter is binding on CBP only for the particular transaction or issue it describes (19 CFR 177.9). Confirm the text and status on CROSS before relying on a ruling. Not legal advice.